xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
LEXINGTON, Mass., Jan. 26, 2016 -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2015 fourth quarter and year-end financial results after the market closes on Tuesday, February 16, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, February 16, 2016, to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-407-4018 (U.S.) or 1-201-689-8471 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call in the Events & Presentations section of the website.
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. The T2Candida Panel was cleared for marketing by the U.S. Food and Drug Administration (FDA) in September 2014 for the detection of sepsis causing Candida. T2Candida Panel performance was established in adult subjects. T2Candida Panel performance in neonates, infants, and pediatric patients has not been established. For more information, please visit www.t2biosystems.com.
Media Contact: Susan Heins, Pure Communications [email protected] 864-286-9597 Investor Contact: Matt Clawson, Pure Communications [email protected] 949-370-8500
